Actavis Inc (ACT) 217.28 $ACT
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014.
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Impax Acquires Generic Products from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 11:00AM CDT
Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for a cash consideration.
Impax reports purchase of two products from Actavis for undisclosed fee
M2 - Thu Jul 03, 6:31AM CDT
Specialist pharmaceutical company Impax Laboratories (NasdaqGS:IPXL) announced on Wednesday the completion of the acquisition of two generic products for cash consideration from Actavis (NYSE:ACT) under a Purchase Agreement and a Supply Agreement.
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Impax Acquires Two Products from Actavis
PR Newswire - Wed Jul 02, 3:05PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
Destination Maternity: Mothercare nixes proposals
AP - Wed Jul 02, 8:03AM CDT
PHILADELPHIA (AP) — Destination Maternity says the U.K.'s Mothercare has rejected two proposals to combine the businesses.
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition
PR Newswire - Wed Jul 02, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest"
regarding their preference as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest.
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
2 Obamacare Supreme Court Ruling "Losers" That Didn't Really Lose
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 01, 12:47PM CDT
Put Obamacare in the losers' bracket this week. On Monday, the U.S. Supreme Court announced a 5-4 decision that prevents the federal government from requiring under the Affordable Care Act that some companies to offer health insurance coverage for...
Actavis closes $28B Forest deal, names new CEO
By The Associated Press - AP - Tue Jul 01, 9:23AM CDT
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Fitch Rates Forest Labs Bonds 'BBB-', Affirms Actavis at 'BBB-'; Outlook Stable
Business Wire - Tue Jul 01, 9:08AM CDT
Fitch Ratings has affirmed Actavis plc (NYSE: ACT) and its subsidiaries at 'BBB-'. In addition, Fitch has assigned a 'BBB-' Issuer Default Rating (IDR) and senior unsecured bonds rating to Forest Laboratories, Inc. (Forest Labs). The Rating Outlook is Stable.
Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition
PR Newswire - Tue Jul 01, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders. The Company also announced that Paul M. Bisaro, formerly the Chairman and Chief Executive Officer of Actavis, has been named to the newly created position of Executive Chairman of the Board of Actavis plc. The changes to the Actavis Board follow the completion of Actavis' acquisition of Forest Laboratories, Inc. in a cash and stock transaction currently valued at approximately $28 billion, and are effective until Actavis' next annual meeting of shareholders in May 2015.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014.
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Impax Acquires Generic Products from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 11:00AM CDT
Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for a cash consideration.
Impax reports purchase of two products from Actavis for undisclosed fee
M2 - Thu Jul 03, 6:31AM CDT
Specialist pharmaceutical company Impax Laboratories (NasdaqGS:IPXL) announced on Wednesday the completion of the acquisition of two generic products for cash consideration from Actavis (NYSE:ACT) under a Purchase Agreement and a Supply Agreement.
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Impax Acquires Two Products from Actavis
PR Newswire - Wed Jul 02, 3:05PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
Destination Maternity: Mothercare nixes proposals
AP - Wed Jul 02, 8:03AM CDT
PHILADELPHIA (AP) — Destination Maternity says the U.K.'s Mothercare has rejected two proposals to combine the businesses.
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition
PR Newswire - Wed Jul 02, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest"
regarding their preference as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
2 Obamacare Supreme Court Ruling "Losers" That Didn't Really Lose
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 01, 12:47PM CDT
Put Obamacare in the losers' bracket this week. On Monday, the U.S. Supreme Court announced a 5-4 decision that prevents the federal government from requiring under the Affordable Care Act that some companies to offer health insurance coverage for...
Actavis closes $28B Forest deal, names new CEO
By The Associated Press - AP - Tue Jul 01, 9:23AM CDT
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Fitch Rates Forest Labs Bonds 'BBB-', Affirms Actavis at 'BBB-'; Outlook Stable
Business Wire - Tue Jul 01, 9:08AM CDT
Fitch Ratings has affirmed Actavis plc (NYSE: ACT) and its subsidiaries at 'BBB-'. In addition, Fitch has assigned a 'BBB-' Issuer Default Rating (IDR) and senior unsecured bonds rating to Forest Laboratories, Inc. (Forest Labs). The Rating Outlook is Stable.
Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition
PR Newswire - Tue Jul 01, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders. The Company also announced that Paul M. Bisaro, formerly the Chairman and Chief Executive Officer of Actavis, has been named to the newly created position of Executive Chairman of the Board of Actavis plc. The changes to the Actavis Board follow the completion of Actavis' acquisition of Forest Laboratories, Inc. in a cash and stock transaction currently valued at approximately $28 billion, and are effective until Actavis' next annual meeting of shareholders in May 2015.
